Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer a drug that helps to prevent the body from absorbing too much potassium compared with a placebo, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.
Published: Apr 23, 2021
SOUTH SAN FRANCISCO, Calif., April 23, 2021 (GLOBE NEWSWIRE) CareDx, Inc., Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced experts will present its latest heart research, which was accepted at the International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, set to take place between April 24-28, 2021.
CareDx’s offerings are showcased through 22 abstracts throughout the ISHLT program. These data selected by the ISHLT organizers, will be presented by prominent thought leaders, highlighting the continued leadership in the cardiothoracic space. Additionally, a CareDx symposium will spotlight leaders in the field of heart and lung transplantation delivering cutting edge content on HeartCare, AlloMap